EI

265.4

-0.56%↓

SAN

86.04

-0.65%↓

MRK1

108.6

+0.51%↑

SHL.DE

47.41

-0.34%↓

ARGX

587

-3.55%↓

EI

265.4

-0.56%↓

SAN

86.04

-0.65%↓

MRK1

108.6

+0.51%↑

SHL.DE

47.41

-0.34%↓

ARGX

587

-3.55%↓

EI

265.4

-0.56%↓

SAN

86.04

-0.65%↓

MRK1

108.6

+0.51%↑

SHL.DE

47.41

-0.34%↓

ARGX

587

-3.55%↓

EI

265.4

-0.56%↓

SAN

86.04

-0.65%↓

MRK1

108.6

+0.51%↑

SHL.DE

47.41

-0.34%↓

ARGX

587

-3.55%↓

EI

265.4

-0.56%↓

SAN

86.04

-0.65%↓

MRK1

108.6

+0.51%↑

SHL.DE

47.41

-0.34%↓

ARGX

587

-3.55%↓

Search

Pharming Group NV

Închisă

1.2 3.63

Rezumat

Modificarea prețului

24h

Curent

Minim

1.15

Maxim

1.213

Indicatori cheie

By Trading Economics

Venit

19M

4.7M

Vânzări

14M

93M

EPS

0.006

Marjă de profit

5.035

Angajați

404

Recomandări

By TipRanks

Recomandări

Cumpărare

Prognoză pe 12 luni

+111.18% upside

Dividende

By Dow Jones

Următoarele câștiguri

6 nov. 2025

Statistici piață

By TradingEconomics

Capitalizare de piață

185M

802M

Deschiderea anterioară

-2.43

Închiderea anterioară

1.2

Pharming Group NV Grafic

Performanțele din trecut nu reprezintă un indicator fiabil al rezultatelor viitoare.

Știri relevante

27 aug. 2025, 22:51 UTC

Câștiguri

Wesfarmers Plans Special Payout to Shareholders as Annual Net Profit Rises 14%

27 aug. 2025, 23:57 UTC

Câștiguri

Trip.com Group 1H Rev $4.01B

27 aug. 2025, 23:57 UTC

Câștiguri

Trip.com Group 1H Adj EPS $1.84

27 aug. 2025, 23:57 UTC

Câștiguri

Trip.com Group 1H EPS $1.82

27 aug. 2025, 23:50 UTC

Market Talk

Nikkei May Decline Amid Caution Over Tariff Impact, Chip Demand -- Market Talk

27 aug. 2025, 23:39 UTC

Câștiguri

Correction to Nvidia Earnings Article -- WSJ

27 aug. 2025, 22:59 UTC

Market Talk

Global Forex and Fixed Income Roundup: Market Talk

27 aug. 2025, 22:59 UTC

Market Talk

HP CEO Sees Strong Back-to-School Spending on PCs -- Market Talk

27 aug. 2025, 22:58 UTC

Câștiguri

South32 Records Significant Items of $71 Million Tied to Worsley, Mozal

27 aug. 2025, 22:57 UTC

Câștiguri

South32 FY Free Cash Flow $192 Million

27 aug. 2025, 22:56 UTC

Câștiguri

South32 FY Total Capital Expenditure $1.35 Billion

27 aug. 2025, 22:56 UTC

Câștiguri

South32 FY Capital Expenditure $963 Million, Excluding EAIs

27 aug. 2025, 22:55 UTC

Câștiguri

South32 Net Cash $123 Million at June 30

27 aug. 2025, 22:54 UTC

Câștiguri

South32: Focused on Maintaining Strong Operating Momentum

27 aug. 2025, 22:53 UTC

Câștiguri

South32: $144 Million Remains to be Returned to Shareholders Under Program

27 aug. 2025, 22:53 UTC

Câștiguri

South32 Extends Capital Management Program for 12 Months

27 aug. 2025, 22:52 UTC

Câștiguri

South32 FY Underlying Ebitda $1.93 Billion, Up 7% On-Year

27 aug. 2025, 22:51 UTC

Câștiguri

South32 FY Revenue $5.78 Billion, Up 17% On-Year

27 aug. 2025, 22:51 UTC

Câștiguri

South32 FY Underlying Earnings $666 Million, Up 75% On-Year

27 aug. 2025, 22:50 UTC

Câștiguri

South32 to Pay Final Dividend of 2.6 U.S. Cents/Share

27 aug. 2025, 22:50 UTC

Câștiguri

South32 FY Net Profit $213 Million Vs $203 Million Loss Year Earlier

27 aug. 2025, 22:45 UTC

Câștiguri

Sandfire Resources Expects FY26 Matsa Capital Expenditure of $148 Million

27 aug. 2025, 22:44 UTC

Câștiguri

Sandfire Resources Expects FY26 Motheo Unit Cost of $44/Ton of Ore Processed

27 aug. 2025, 22:44 UTC

Câștiguri

Sandfire Resources Expects FY26 Motheo Capital Expenditure of $82 Million

27 aug. 2025, 22:43 UTC

Câștiguri

Sandfire Resources Expects FY26 Matsa Unit Cost of $86/Ton of Ore Processed

27 aug. 2025, 22:43 UTC

Câștiguri

Nvidia Breaks Sales Record Despite Chinese Trade Hiccups -- 5th Update

27 aug. 2025, 22:42 UTC

Câștiguri

Sandfire Resources Expects FY26 Motheo Copper Eq Output to Rise 3% to 61,000 Tons

27 aug. 2025, 22:42 UTC

Câștiguri

Sandfire Resources Expects FY26 Matsa Copper Eq Output to Rise 2% to 96,000 Tons

27 aug. 2025, 22:40 UTC

Câștiguri

Sandfire Resources Net Debt $123 Million at June 30

27 aug. 2025, 22:40 UTC

Câștiguri

Sandfire Resources FY Underlying Ebitda $527.7 Million

Comparație

Modificare preț

Pharming Group NV Așteptări

Obiectiv de preț

By TipRanks

111.18% sus

Prognoză pe 12 luni

Medie 2.45 EUR  111.18%

Maxim 2.45 EUR

Minim 2.45 EUR

În baza a 1 analiști de pe Wall Street care oferă obiective de preț pe 12 luni pentruPharming Group NV - Dist în ultimele 3 luni.

Consens privind evaluarea

By TipRanks

Cumpărare

1 ratings

1

Cumpărare

0

Păstrare

0

Vânzare

Date financiare

Cheltuieli de vânzare și administrare

Cheltuieli de exploatare

Profit pre-impozitare

Vânzări

Costul vânzărilor

Profit brut din vânzări

Cheltuieli cu dobânzile pe datorie

EBITDA

Profit operațional

$

Despre Pharming Group NV

Pharming Group N.V., a biopharmaceutical company, develops and commercializes protein replacement therapies and precision medicines for the treatment of rare diseases in the United States, Europe, and internationally. The company offers RUCONEST, a recombinant C1 esterase inhibitor for the treatment of acute attacks in adult and adolescent patients with acute hereditary angioedema (HAE); and Joenja (leniolisib), an oral small molecule PI3K" inhibitor for the treatment of activated phosphoinositide 3-kinase delta syndrome. It also develops OTL-105, an investigational ex-vivo autologous hematopoietic stem cell gene therapy for the treatment of HAE. The company has a development collaboration and license agreement with Novartis; and a strategic collaboration agreement with Orchard Therapeutics plc for research, development, manufacturing, and commercialization of OTL-105. Pharming Group N.V. was incorporated in 1988 and is headquartered in Leiden, the Netherlands.